340B Sales Growth Rate Softened for Second Straight Year, Data Show

IQVIA
Prescription drug sales at 340B prices softened for the second consecutive year compared with sales growth from 2019 to 2020, data in a new IQVIA white paper show.

Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth from 2020

Read More »

Exelixis Puts 45-Day Limit on Requests to Reclassify Past Sales as 340B Purchases

Exelixis
Exelixis says starting May 15 it will honor 340B covered entities' requests to replenish/reclassify prior purchases that were not made at the 340B ceiling price only within 45 days of the date that the drug was dispensed.

Starting May 15, biopharmaceutical manufacturer Exelixis will require 340B covered entities that want past drug purchases that were not made at the 340B ceiling price to be reclassified as 340B sales to do so within 45 days of the date

Read More »

340B-Related Amendment Might Be Offered to PBM Reform Bill That Senate Panel Is Trying to Mark Up Today

Mike Braun
Sen. Mike Braun (R-Ind.) is expected offer an amendment in committee today to PBM reform legislation to require 340B hospitals to be more transparent about how they use 340B program savings.

A U.S. Senate committee is attempting to mark up bipartisan legislation today to reform the pharmacy benefit management industry. The draft bill itself does not address the 340B program. Republican Sen. Mike Braun (Ind.), however, has filed an amendment for

Read More »

Judge Denies Health Center’s Request for More Government Files in 340B Patient Definition Case

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.

A federal district judge last week declined to make federal health officials give a South Carolina health center any more documents linked to the center’s brief expulsion from and subsequent reinstatement to the 340B program in 2018.

U.S. Chief District

Read More »

340B Stifles Biosimilar Uptake, Study in Health Affairs Says

Health Affairs
New research in Health Affairs says 340B hospitals are less likely than others to use biosimilar drugs due to financial incentives to use more expensive reference drugs instead.

Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.”

Groups that represent

Read More »

News Alert

Bayer Announces Tougher Limits on 340B Pricing for Hospitals

Bayer
Bayer today significantly tightened its limits on 340B pricing when hospitals contract with pharmacies to dispense drugs to patients.

Drug manufacturer Bayer this morning significantly tightened its limits on 340B pricing when hospital covered entities contract with pharmacies to dispense drugs to patients. Grantee entities remain exempt from Bayer’s restrictions.

Covered entities reported receiving letters from Bayer about

Read More »

AHA Tells House Panel It Opposes New 340B Hospital Reporting Requirements

Ashley Thompson
“I'm just not sure additional [340B hospital] reporting requirements are needed at this time,” AHA Senior Vice President Ashley Thompson told a U.S. House subcommittee yesterday.

An American Hospital Association senior executive told a U.S. House subcommittee yesterday her group opposes creating “significant new reporting requirements for 340B hospitals that do not reflect the true value or intent of the 340B program.”

But when asked by

Read More »

Louisiana Takes Major Step Towards Prohibiting Drug Manufacturer 340B Contract Pharmacy Restrictions

Louisiana House
The Louisiana House voted 97-2 to approve legislation to stop drug manufacturer interference with 340B contract pharmacy arrangements and prohibit PBM and payor practices that lower reimbursement for 340B-purchased drugs.

The Louisiana House voted 97-2 yesterday to pass and send to the Senate legislation to stop drug manufacturer interference with 340B contract pharmacy arrangements. It also would prohibit pharmacy benefit manager and payor practices that lower reimbursement for 340B-purchased drugs.

Read More »

A Cheat Sheet to New Groups that Use “340B” in Their Names

Cheat Sheet
340B Report Publisher and CEO Ted Slafsky's latest column for Verity Solutions is a cheat sheet for the growing number of groups using "340B" in their names.

With so many advocacy groups using the term “340B” in their name these days, it’s easy to confuse one with another. Ted Slafsky’s latest column for Verity Solutions is a guide to the menagerie.

Slafsky, publisher and CEO of 340B

Read More »

340B Recertification for CDC Grantees Starts May 8

Recertification
Annual 340B recertification for CDC grantees will be May 8 through June 5.

This year’s annual 340B recertification period for U.S. Centers for Disease Prevention and Control grantees—Title X family planning, sexually transmitted disease, and tuberculosis clinics—will be May 8 through June 5, the U.S. Health Resources and Services Administration said Tuesday.

Recertification

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live